Aurion Biotechnologies

Based in Seattle, Boston and Tokyo, Aurion Biotech is a clinical-stage biotech company. Our mission is to cure leading forms of blindness and transform the lives of millions of patients, by developing a platform of advanced therapies to treat ocular diseases. Our first candidate is for the treatment of corneal edema, and one of the first clinically validated cell therapies for corneal care. Healthy cells from a donor cornea are cultured in a novel, multi-step, proprietary and patented process. Cells from a single donor can be used to treat more than 100 recipient eyes. In clinical trials in Japan, patients have experienced significant and durable improvements in key measures of corneal health: visual acuity, corneal endothelial cell density and corneal thickness.

Aurion Biotechnologies headquartered in United States, North America, operates in the Biotechnology, Health Care, Medical, Biopharma sector. The company focuses on Biotechnology and has secured $1.9B in funding across 16 round(s). With a team of 11-50 employees, Aurion Biotechnologies is actively contributing to advancements in Biotechnology. Their latest funding round, Venture Round - Aurion Biotechnologies, raised $120.0M. Discover more about their projects, partnerships, and impact on our platform.